Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD
BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is being led by chair Brian Leedman - a founder of ResApp Health - the cough analysis app sold to Pfizer two years ago in a $179 million deal.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
AFT | Ann: AFT makes further progress in international markets | 04/03/24 | 0 | 85 | |||
|
|||||||
AFT | Ann: AFT updates operating profit guidance to $23m to $25m | 16/02/24 | 0 | 117 | |||
|
|||||||
AFT | Ann: Maxigesic IV launched in the United States | 07/02/24 | 0 | 66 | |||
|
|||||||
AFT | Ann: AFT further broadens R&D pipeline with new product | 19/01/24 | 0 | 74 | |||
|
|||||||
AFT | Ann: NEW YEAR LETTER TO INVESTORS | 09/01/24 | 0 | 112 | |||
|
|||||||
AFT | Ann: AFT broadens R&D pipeline with new product candidate | 22/12/23 | 0 | 60 | |||
|
|||||||
AFT | Ann: AFT Pharma reports growth and global expansion | 23/11/23 | 0 | 130 | |||
|
|||||||
AFT | Ann: AFT's Crystaderm(R) antiseptic approved for sale in China | 21/11/23 | 0 | 56 | |||
|
See All Discussions